Cardiol Therapeutics Appoints Thomas Moffatt as Chief Commercial Officer
Oakville, Ontario--(Newsfile Corp. - March 6, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, is pleased to announce the appointment of Thomas (Tom) Moffatt, BBA, as Chief Commercial Officer. Mr. Moffatt was most recently the Chief Operating Officer and Vice-President, Operations at Rx Drug Mart Inc., where he was...
2019-03-06 8:37 AM EST
Cardiol Therapeutics Inc. Closes Over-Allotment
Oakville, Ontario--(Newsfile Corp. - January 18, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announced today that the underwriters for the Company's initial public offering (the "Offering") have exercised their over-allotment option (the "Over-Allotment Option") to purchase an additional 374,544 Class A common shares of...
2019-01-18 9:14 AM EST
Cardiol Therapeutics Completes Initial Public Offering and the Company's Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols "CRDL" and "CRDL.WT"
Oakville, Ontario--(Newsfile Corp. - December 20, 2018) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announces that it has completed its initial public offering (the "IPO") on the Toronto Stock Exchange (the "TSX"). In connection with the IPO, Cardiol issued (a) 3,000,000 units (the "Units") at a price of $5.00 per Unit, with...
2018-12-20 9:27 AM EST
Cardiol Therapeutics Announces Filing of Preliminary Prospectus
Oakville, Ontario--(Newsfile Corp. - September 17, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a biotechnology company specializing in the research and commercial development of novel drug therapies utilizing proprietary drug-delivery systems, is pleased to announce that it has filed a preliminary prospectus with the securities regulatory authorities in each of the provinces of Canada, except Quebec, in connection with a proposed initial public offering (the "Offering") of...
2018-09-17 4:03 PM EDT
Cardiol Therapeutics Appoints Mr. Chris Waddick as Chief Financial Officer, Ms. Anne Tomalin as Director of Regulatory Affairs, and Ms. Dolly Kao as Intellectual Property Counsel
Oakville, Ontario--(Newsfile Corp. - August 30, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company") is pleased to announce the appointment of Mr. Chris Waddick, MBA, CPA, as Chief Financial Officer, Ms. Anne Tomalin, BA, BSc, RAC, as Director of Regulatory Affairs, and Ms. Dolly Kao, BSc, JD, as Intellectual Patent Counsel. Mr. Chris Waddick, MBA, CPA, has thirty years of experience in financial and executive roles in the biotechnology and energy industries, with substantial...
2018-08-30 10:21 AM EDT
Cardiol Therapeutics Appoints Dr. Eldon Smith as Chairman and Ms. Deborah Brown, Mr. Iain Chalmers, and Dr. Guillermo Torre-Amione to its Board of Directors
Oakville, Ontario--(Newsfile Corp. - August 21, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart, is pleased to announce the appointment of Dr. Eldon Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC, as Chairman, and Ms. Deborah Brown, MBA, Mr. Iain Chalmers, MBA, and Dr. Guillermo...
2018-08-21 10:13 AM EDT
Cardiol Therapeutics Closes CDN$10.5 Million Private Placement
Toronto, Ontario--(Newsfile Corp. - May 24, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart, is pleased to announce the successful closing of a brokered private placement (the "Private Placement") of approximately CDN$10.5 million principal amount of unsecured convertible...
2018-05-24 8:36 AM EDT
Cardiol Therapeutics Appoints Dr. James Young as Chair of the Company's Scientific Advisory Board
Toronto, Ontario--(Newsfile Corp. - May 8, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that it has appointed Dr. James Young as Chair of the Company's Scientific Advisory Board. Dr. Young is Professor of Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Chief...
2018-05-08 1:49 PM EDT
Cardiol Therapeutics to Present at the 2018 BIO CEO & Investor Conference in NYC
Toronto, Ontario--(Newsfile Corp. - February 6, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that it will be presenting at the 2018 BIO CEO & Investor Conference, to be held February 12th and 13th, in New York City. Cardiol's President and CEO, David Elsley, will present a corporate overview on Tuesday,...
2018-02-06 10:07 AM EST
Cardiol Therapeutics Demonstrates Novel Way to Target Drugs for Treating Heart Failure Using Nanotechnology
Toronto, Ontario--(Newsfile Corp. - January 9, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that experimental research performed at the Houston Methodist DeBakey Heart & Vascular Center, Texas, shows new functionality of the Company's patented nanotherapeutics. Designed to act as a vehicle to target...
2018-01-09 7:03 AM EST
Cardiol Therapeutics to Present at the 2018 Biotech Showcase in San Francisco
Oakville, Ontario--(Newsfile Corp. - January 3, 2018) - Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that it will be presenting at the 2018 Biotech Showcase in San Francisco. Cardiol's President and CEO, David Elsley, will present a corporate overview on Tuesday, January 9th, 2018 at 2 PM PST at the Hilton San...
2018-01-03 8:03 AM EST